Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 6, 2014, Pages 630-639

  Abbas, Zaigham ^a   Yakoob, Javed ^a   Jafri, Wasim ^a   Ahmad, Zubair ^a   Azam, Zahid ^a   Usman, Muhammad W ^a   Shamim, Sara ^a   Islam, Muhammad ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Cytokine; irritable bowel syndrome; probiotic; Saccharomyces boulardii

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; ISPAGULA; PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DEFECATION HABIT; DIARRHEA; DIARRHEA DOMINANT IRRITABLE BOWEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPITHELIUM CELL; FEMALE; FLATULENCE; GOBLET CELL; HEARTBURN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LYMPHOCYTE; MALE; MITOSIS; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES BOULARDII; SOMNOLENCE; TISSUE LEVEL; COLON; COMPLICATION; IMMUNOLOGY; INTESTINE MUCOSA; IRRITABLE BOWEL SYNDROME; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOMETRY; SACCHAROMYCES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; COLON; CYTOKINES; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; PSYCHOMETRICS; QUALITY OF LIFE; SACCHAROMYCES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900435971     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000094     Document Type: Article

References (43)

1. McFarland L, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14:2650-2661
2. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year followup study. Gut 2007; 56:321-327
3. Cain KC, Headstrom P, Jarret ME, Motzer SA, Park H, Burr RL, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101:124-132
4. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7:163-173
5. Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, et al. Th e immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011; 4:349-359
6. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
7. Malinen E, Rinttila T, Kajander K, Mä ttö J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382
8. Thabane M, Kottachchi DT, Mars hall JK. Systematic review and metaanalysis: incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:535-544
9. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131:445-450
10. Shanahan F. Irritable bowel syndrome: shifting the focus toward the gut microbiota. Gastroenterology 2007; 133:340-342
11. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39:237-238
12. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16:2202-2222
13. Hatoum R, Labrie S, Fliss I. Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Front Microbiol 2012; 3:421
14. Dahan S Dalmasso G Imbert V Peyr on JF Rampal P Czerucka D, Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells, Infect Immun, 2003,71, 766-773.
15. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O? Brien M, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo, and protects agains t Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006; 281:24449-24454
16. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, et al. Saccharomyces bou lardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343:69-76
17. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome: double blind trial of Saccharomyces boulardii. Med Chir Dig 1983; 12:77-79
18. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008; 135:568-579
19. Rome III diagnostic criteria for functional gastrointesinal disorders. Available at: http://www.romecriteria.org/assets/pdf/19-RomeIII-apA-885-898.pdf. [Accessed 18 March 2014]
20. O? Donnell L, Virjee J, Heaton KW. Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. Br Med J 1990; 300:439-440
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159
22. Lagrelius M, Jones P, Franck K, Gaines H. Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytoki ne 2006; 33: 156-165
23. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocyt apheresis. Am J Gastroenterol 2002; 97: 2820-2828
24. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6:986-994
25. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2 007; 133:1099-1105
26. Drossman DA, Patrick DL, WhiteHead WE, Toner BB, Diamant NE, Hu Y. Further validation of the IBS-QOL: a disease specific quality of life questionnaire. Am J Gastroentero 2000; 95:999-1007
27. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and up-date. Clin Colon Rectal Surg 2012; 25:46-52
28. Labus J, Gupta A, Gill HK, Posserud I, Mayer M, Raeen H, et al. Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther 2013; 37:304-315
29. Mahvi-Shirazi M, Fathi-Asthiani A, Rasoolzade-Tabatabaei SK, Amini M. Irritable bowel syndrome treatment: cognitive behavioral therapy versus medical treatment. Arch Med Sci 2012; 8:123-129
30. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-332
31. Simré n M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62:159-176
32. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn?s disease. Dig Dis Sci 2000; 45:1462-1464
33. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15:697-698
34. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131:1812-1825
35. Thomas S Przesdzing I Metzke D Schmitz J Radbruch A Baumgart DC, Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation, Clin Exp Immunol, 2009,155, 78-87.
36. Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999; 42:261-264
37. Chadwick VS, ChenW , Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778-1783
38. Barbara G, Wang B, Stanghel lini V, de Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neuronsin irritable bowel syndrome. Gastroenterology 2007; 132:26-37
39. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome. Effect on quality of life. J Clin Gastrenterol 2 011; 45:679-683
40. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr R es 2008; 43:164-174
41. Elli M, Cattivelli D, Soldi S, Bonatti M, Morelli L. Evaluation of prebiotic potential of refined psyllium (Plantago ovata) fiber in healthy women. J Clin Gastroentero l 2008; 42:S174-S176
42. Mehmood MH, Aziz N, Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of psyllium husk (ispaghula) in constipation and diarrhea. Dig Dis Sci 2011; 56:1460-1471
43. Rodŕ guez-Cabezas ME, Gá lvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr 2003; 22:463-471